Vera Therapeutics stock jumps after the FDA approved its autoimmune kidney drug
Trutakna, priced at $425,000 per year, is the first drug approved in the U.S. that targets both BAFF and APRIL proteins linked to IgA nephropathy
Overview
Trutakna, priced at $425,000 per year, is the first drug approved in the U.S. that targets both BAFF and APRIL proteins linked to IgA nephropathy
Source
Originally published at qz.com.
Related Articles
- SambaNova raised $1 billion at an $11 billion valuation as investors back Nvidia challengers
- Tourists stranded after travel agency files for bankruptcy and cancels all trips
- Famed investor Jeremy Grantham says history will end up laughing at SpaceX, the ‘craziest IPO in the history of man’ that just joined the Nasdaq 100
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
